Keep your patients in remission, get ahead of their recurrence

We identify and target the drivers of recurrence and monitor ctDNA to catch disease before it's visibile on scans

Thank you. A member of our team will reach out to you shortly.

Oops! Something went wrong while submitting the form.

"In today's world of personalized cancer therapy it's important to understand the genetic and metabolic fingerprint of each tumour in order to determine the most appropriate combinations of drugs"

Dr Andrew Gaya

Consultant Clinical Oncologist at the Cromwell Hospital

"Astron's evidence-based innovation..... could rapidly become a transformative approach to oncology"

Dr Ndaba Mazibuko

Research Fellow at Kings College London

Our team have led teams and studied at some of the world's top research organisations

How we target the drivers of recurrence, tolerably

Molecular tests can identify 1000s of mutations, but conventional precision oncology only targets fewer than 50 of these, limiting its ability to target the drivers of recurrence. Our bioinformatic drug repurposing research lets us match 40x more drivers than current precision oncology. Our treatment recommendations are peer reviewed, well understood and highly tolerable, so they are well suited for use in remission.

How Astron Works

Molecular Analysis

We conduct testing to identify the specific genomic drivers of cancer recurrence

Targeted Treatment Planning

We use bioinformatics to match treatments to your patient’s specific recurrence drivers

Quarterly Monitoring

We test for Minimum Residual Disease to detect cancer at the molecular level before visible on scans

Treatment Adaptation

We adjust the personalized treatment protocol based on quarterly monitoring results

When can you use Astron in your practice?

After curative treatment

Prevent recurrence and stabilize the disease after a cycle of treatment.

After any cycle of treatment

Monitor for progression so that you keep in front of the disease.

After imaging or symptom progression

Adapt therapies based on tumor evolution and emerging resistance mechanisms.

Upon confirmation of cancer

Establish a baseline molecular profile of the tumor to guide treatment decisions.

Why partner with Astron?

Maximize curative treatment cycles for each patient

Save time on monitoring appointments

Co-authoring opportunities for peer reviewed publications

AI-driven treatment insights based on real-world data

Personalized evidence-based treatment options for patients in remission

Get more patients by offering precision oncology services

Peace of mind for your patients

What patients are saying about Astron

"With these treatments I've got optionality and that makes a huge difference psychologically"

Paul

Astron Patient

"Practically tackling issues specific to my cancer has quite simply been life changing"

Judith

Astron Patient

"I've taken control in some way, you know. I want to know I've ticked every box."

Carol

Astron Patient

Current Clinical Research

An observational study evaluating longitudinal Minimal Residual Disease (MRD) status in potentially curable Pancreatic Ductal Adenocarcinoma (PDAC) following definitive treatment.

Get your practice involved in co-authoring our ground breaking clinical study or clinical registry study at the forefront of precision oncology.

Learn More

Become a founding Astron Partner

Collaborating with Astron can enhance patient outcomes, streamline clinic operations and success whilst provide opportunities for co-authoring in leading scientific publications.

Become A Partner